About US
Contact us
-
Thermo Fisher, Charles River join robotics outfit Multiply Labs' quest to automate cell therapy productionOn a quest to automate manual portions of the cell therapy production process, Multiply Labs is arming itself with two more pieces of industry-leading tech. The new kit comes on board a little less t2022/5/6
-
Pfizer and BioNTech seek FDA EUA for Covid-19 booster in childrenPfizer and BioNTech have submitted anapplicationseeking Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a 10µg booster dose of their Covid-19 vaccine in children2022/4/28
-
Cytovia signs business combination agreement with IsleworthCytovia has signed a definitive business combinationagreementwith special purpose acquisition company (SPAC) Isleworth Healthcare Acquisition to create a publicly listed company focusing on natural k2022/4/28
-
Is AstraZeneca finally ready to score with underachieving cancer drug tremelimumab?After years of failing to live up to expectations in a variety of cancer types, is AstraZeneca’s tremelimumab staging a better-late-than-never rally? Less than a year ag2022/4/26
-
COVID-19 tracker: US government will make Pfizer's Paxlovid available at all pharmaciesUnder a Biden administration plan, Pfizer's Paxlovid will soon be available at all U.S. pharmacies. The White House COVID-19 response coordinator says hospitalizations a2022/4/26
-
COVID-19 tracker: UK study finds strong responses 84 days after booster shotA U.K. study documented strong immune responses from various booster vaccines. CureVac and GlaxoSmithKline announced positive preclinical data for their new variant-specificmRNA vaccine candida2022/4/22
-
In Repatha patent feud, Supreme Court asks United States' top lawyer to weigh Amgen's appealThe U.S. Supreme Court is breaking out the big guns to help make sense of Amgen and Sanofi's long-running PCSK9 patent feud. “The Solicitor General is invited to file a2022/4/22
-
BeiGene nabs another PD-1 approval in China. Can partner Novartis carry the success to US and Europe?With the lack of success of its PD-1/L1 candidate spartalizumab, Novartis last year decided to buy its way into the arena. So it struck a deal with BeiGene of China, paying $650 million up front and2022/4/19
-
Could Pfizer's Paxlovid or other antivirals help cure long COVID?While the biopharmaceutical industry has been quick to develop vaccines, antibodies and antiviral remedies to combat the coronavirus, one area that has remained elusive for researchers is long COVID.2022/4/19
-
The mysterious case of Viatris and the missing insulin label deepensViatris and the case of the missing insulin label is getting a second act. Mylan Pharmaceuticals, now flying the Viatris banner, said Tuesday that it wasrecallingone lot of insulin glargine inj2022/4/14